Navigation Links
New discovery may lead to effective prevention and treatment of graft-versus-host dsease
Date:4/1/2012

Bethesda, MD -- A new discovery in mice may lead to new treatments that could make bone marrow transplants more likely to succeed and to be significantly less dangerous. According to new research findings published in the Journal of Leukocyte Biology (https://www.jleukbio.org) Brazilian scientists may have found a way to prevent the immune system from attacking transplant grafts and damaging the host's own cells after a bone marrow transplant.

Specifically, they found that a receptor for a mediator of the inflammatory process, known as platelet activating factor plays a crucial role in the development of graft-versus-host disease. Platelet activating factor receptor appears to contribute to the attraction of immune cells that lead to graft-versus-host disease. When this mechanism was blocked, there was reduced tissue damage and mortality.

"Platelet activating factor receptor antagonists may decrease suffering caused by graft-versus-host disease in patients undergoing bone marrow transplant," said Vanessa Pinho, Ph.D., a researcher involved in the work from the Departamento de Morfologia, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais in Brazil. "As graft-versus-host disease also may decrease quality of life, patients treated with platelet activating factor receptor antagonists may live longer and with better quality of life."

To make this discovery, scientists induced graft-versus-host disease by transferring cells between mice which were genetically incompatible. In mice subjected to graft-versus-host disease, there was significant injury to target organs, especially the liver and the intestine. In mice that received cells from genetically modified mice bred to not have platelet activating factor receptors, or in mice treated with platelet activating factor receptor antagonist, there was reduced tissue injury and reduced lethality.

"Immune rejection is one of the biggest risks of any transplant procedure, and this study sheds a new light on a receptor and pathway amenable to therapeutic intervention to reduce the serious complication of graft-versus-host disease," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "The next step is to take these observations from the lab and see if the potential suggested by studies in mice hold true in humans with disease."


'/>"/>
Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Tales from the crypt lead researchers to cancer discovery
2. Breast cancer risk gene discovery fast tracked by new technology
3. Discovery offers insight into treating viral stomach flu
4. Unexpected discovery reveals a new mechanism for how the cerebellum extracts signal from noise
5. Discovery provides blueprint for new drugs that can inhibit hepatitis C virus
6. Annual Drug Discovery Conferences Being Held in Boston MA, Spring 2012
7. Discovery of a molecule that initiates maturation of mammalian eggs can lead to more IVF pregnancies
8. A*STAR scientists make groundbreaking discovery on stem cell regulation
9. A biodiversity discovery that was waiting in the wings -- wasp wings, that is
10. OHSU discovery may someday lead to prevention and treatment of sudden infant death syndrome
11. Notre Dame researchers report fundamental malaria discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/11/2017)... -- Michael Johnson, co-founder of Visikol Inc. a company originally funded with ... to the elite "Forbes 30 Under 30" list in the Science ... 20 fields nationwide to be recognized as a leader in business ... ... a PhD candidate at Rutgers University. Visikol ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... biometric sensor technology, today announced the launch of ... sensor systems, the highly-accurate biometric sensor modules that ... biometric technology, experience and expertise. The two new ... designed specifically for hearables, and Benchmark BW2.0, a ...
Breaking Biology News(10 mins):
(Date:1/24/2017)... - BioAmber Inc. (NYSE: BIOA ) today announced ... Rodman & Renshaw, a unit of H.C. Wainwright ... representative of several underwriters, under which the underwriters have ... minimum of 2,105,264 shares of common stock of the ... 1,052,632 shares of common stock of the Company with ...
(Date:1/23/2017)...   Enteris BioPharma, Inc. , announced today the ... to leverage Enteris, proprietary and patented oral peptide ... oral formulation of one of Sanofi,s preclinical stage peptides. ... Officer and Executive Chairman of Enteris BioPharma, remarked, "Our ... value our Peptelligence platform program offers in the therapeutic ...
(Date:1/23/2017)... Township, PA (PRWEB) , ... January 23, 2017 ... ... P. Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety ... University of Madras in India. , Dr. Thomas’ career as an academic ...
(Date:1/23/2017)... Utah (PRWEB) , ... January 23, 2017 , ... ... been named an INTERNET TELEPHONY Product of the Year Award winner for 2017. ... industry leader in unified communications solutions. In 2016, CallTower was awarded with the hosted ...
Breaking Biology Technology: